PMC5138021_01
Upper left: fundus fluorescein angiography image in late arteriovenous phase of the posterior pole, including the posterior margin of the tumor before intravitreal injection of dexamethasone. Lower left: infrared image of the tumor. Right: color fundus photography of the posterior pole before intravitral injection showing retinal exudates, microaneurysms, and narrowing of retinal vessels with focal irregularities.
imcrj-9-377Fig1.jpg
PMC5138021_01_imcrj-9-377Fig1.jpg
f1-imcrj-9-377
No signs of retinal ischemia were observed on FFA images, but an area of hypofluorescence in the foveal region was evident (Figure 1).
Upper row: foveal and para-foveal 180  OCT B-scans before intravitreal injection of dexamethasone implant showing foveal serous detachment, intraretinal cysts, and exudates. Lower row: foveal 60  OCT B-scans 2 months (A), 8 months (B), and 16 months (C) after the treatment.. Abbreviation: OCT, optical coherence tomography.
imcrj-9-377Fig2.jpg
PMC5138021_01_imcrj-9-377Fig2.jpg
f2-imcrj-9-377
RME was classified to grade 2 and SD-OCT images showed foveal neuroepithelium detachment, intraretinal cysts, and hard exudates (Figure 2). Retinal thickness map calculated by the Spectralis HRA+OCT mapping software shows a clinically significant RME and a central foveal thickness (CFT) of 500 microm (Figure 3). After the foveal detachment restoration, no disruption nor discontinuity of the ellipsoid zone was evident (Figure 2).
Retinal thickness charts calculated by the Spectralis HRA + optical coherence tomography mapping software show increased retinal thickness due to CSRME 20 days before treatment (upper chart), partial persistence of ME inferiorly and nasally to the fovea (central chart), and further reduction of retinal thickness ~16 months after treatment (lower chart).
imcrj-9-377Fig3.jpg
PMC5138021_01_imcrj-9-377Fig3.jpg
f3-imcrj-9-377
RME was classified to grade 2 and SD-OCT images showed foveal neuroepithelium detachment, intraretinal cysts, and hard exudates (Figure 2). Retinal thickness map calculated by the Spectralis HRA+OCT mapping software shows a clinically significant RME and a central foveal thickness (CFT) of 500 microm (Figure 3). CFT decreased from 500 to 419 microm after 15 days and to 213 microm after 2 months, then it progressively increased to 285 microm at 8 months, leveling-off at 269 microm by the end of the follow-up (Figure 3).